We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use a cost utility analysis to evaluate your digital health product.
This collection brings together guidance and associated documents relating to alternative pricing
How to show the MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
What best available techniques are, when you must follow them, how to propose alternatives and how to refer to them in your application.
How manufacturers can apply for approval to supply a non-compliant medical device on humanitarian grounds.
How to use a randomised controlled trial to evaluate your digital health product.
Lassa virus causes Lassa fever, an acute viral haemorrhagic fever (VHF).
Comply with good manufacturing practice (GMP) and good distribution practice (GDP), and prepare for an inspection.
Guidance for industry on flexible approaches we are taking on good distribution practices.
We are allowing alternative courses of actions for manufacturing or laboratory equipment during the outbreak.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).